Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

News SummaryMost relevantAll newsSector newsTweets 

Merck Combination Cholesterol Drug Fails to Meet Study Goals; Firm Doesn't Plan to Seek U.S. Approval

share with twitter share with LinkedIn share with facebook
share via e-mail
12/20/2012 | 03:17pm CEST
   By Tess Stynes 

Merck & Co. (>> Merck & Co., Inc.) said its doesn't plan to seek U.S. Food and Drug Administration for a combination cholesterol treatment that aims to reduce the risk of cardiovascular events after the drug failed to meet primary goals in a large long-term study.

Shares were down 2.9% at $42.40 in premarket trading.

The pharmaceutical giant said it isn't recommending that health-care providers start new patients on the treatment--Tredaptive--an extended release combination of niacin and laropiprant. The company also plans to share the study results with health regulators in countries where it also is approved under the Tredaptive or Cordaptive brands.

"While we are disappointed in these results, we thank the investigators who have conducted the study and the patients who have participated in it," said Peter S. Kim, president, Merck Research Laboratories.

The study that compared extended-release niacin and laropiprant plus statin therapy versus statin therapy included 25,673 patients in Britain, Scandinavia and China considered at risk for cardiovascular issues that were followed for a median 3.9 years.

The study found that the combination drug along with statin therapy didn't significantly further reduce the risk of a combination of cardiovascular events such as nonfatal heart attacks, strokes or coronary-related deaths compared with just statin therapy. There also was an increase in nonfatal events in the group receiving Tredaptive.

Further analysis is under way and detailed study results are expected in the first quarter.

Write to Tess Stynes at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Merck & Co., Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on MERCK AND COMPANY
12:16p RANSOMWARE : How to fight it
06/28 MERCK AND : Colombia takes historic step to peace as rebels lay down guns; NEWS ..
06/28DJMERCK AND : Today's Top Supply Chain and Logistics News From WSJ
06/28 MERCK : New cholesterol drug worked in big study Merck says new type of choleste..
06/28 Factbox - Companies hit by global ransomware attack on June 27
06/28 MERCK AND : hack part of a massive global attack
06/27DJMERCK AND : Says Its Network Was Hit by Global Hack
06/27 MERCK AND : is the target of a massive hack
06/27 Ransomware attack causes disruptions across globe
06/27 MERCK AND : says new type of cholesterol drug worked in big study
More news
Sector news : Pharmaceuticals - NEC
09:22a COVESTRO : vows to cash out to shareholders if no takeover on cards
04:55a MYLAN : Investors call on Mylan chairman, director to step down
06/28 UK blue chips led lower by Hargreaves as strong pound takes toll
06/28DJVECTURA : In Asthma Collaboration With Novartis's Sandoz
06/28DJGLAXOSMITHKLINE : Announces US Filing For Mepolizumab
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
07:39a Syndax Locks In To Tumor Escape
06/28 Merck's Cautious Statement Suggests Slim Chances Of Anacetrapib Success
06/28 Opportunities In Cyber Security After Growing Number Of Ransomware Attacks
06/28 Comments On REVEAL, Merck's CTEP Inhibitor Study
06/28 WALL STREET BREAKFAST : Fed's Stress Tests - Part 2
Financials ($)
Sales 2017 39 964 M
EBIT 2017 13 664 M
Net income 2017 7 128 M
Debt 2017 3 171 M
Yield 2017 2,88%
P/E ratio 2017 25,40
P/E ratio 2018 18,98
EV / Sales 2017 4,54x
EV / Sales 2018 4,40x
Capitalization 178 223 M
More Financials
Duration : Period :
Merck and Company Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Full-screen chart
Technical analysis trends MERCK AND COMPANY
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 69,4 $
Spread / Average Target 6,4%
Consensus details
EPS Revisions
More Estimates Revisions
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis Chief Financial Officer & Executive Vice President
Clark Golestani Chief Information Officer & Executive VP
Thomas Henry Glocer Independent Director
Rochelle B. Lazarus Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MERCK AND COMPANY10.68%178 223
JOHNSON & JOHNSON17.19%360 489
ROCHE HOLDING LTD.8.34%226 454
NOVARTIS11.74%223 476
PFIZER3.91%200 985
SANOFI12.74%124 566
More Results